Profile data is unavailable for this security.
About the company
Adcock Ingram Holdings Limited is a South Africa-based healthcare company. The Company is engaged in supplying specialty, branded and generic pharmaceutical products, hospital products, and fast-moving consumer goods (FMCG). Its segments include Consumer, Over the Counter (OTC), Prescription, Hospital, and Other. The Consumer segment is engaged mainly in the FMCG retail space. Its OTC segment focuses on brands sold predominantly in pharmacies. Its Prescription segment markets products prescribed by medical practitioners, and specialized instruments and surgical products. Its Hospital segment supplies hospital and critical care products, including intravenous solutions, blood collection products and renal dialysis systems. Its Other segment includes shared services and other support services, including regulatory services in India, as well as the investment in the Indian joint venture and cash and bank overdraft balances which are managed on a central basis in Southern Africa.
- Revenue in ZAR (TTM)9.64bn
- Net income in ZAR814.01m
- Incorporated2007
- Employees2.39k
- LocationAdcock Ingram Holdings Ltd1 New Road, (c/o New Road & 7th Street)MIDRAND 1682South AfricaZAF
- Phone+27 116350000
- Fax+27 865530000
- Websitehttps://www.adcock.co.za/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Soho Global Health Tbk PT | 10.44bn | 507.33m | 9.66bn | 2.35k | 19.04 | 3.22 | 16.51 | 0.9255 | 34.94 | 34.94 | 718.57 | 206.80 | 1.78 | 5.47 | 5.14 | 3,843,169,000.00 | 8.66 | 7.97 | 16.02 | 14.37 | 15.82 | 19.39 | 4.86 | 4.65 | 1.28 | -- | 0.0054 | -- | 12.45 | 12.43 | 4.10 | 49.70 | 21.21 | -- |
| Beijing Luzhu Biotechnology Co Ltd | 0.00 | -692.59m | 10.30bn | 148.00 | -- | 4.44 | -- | -- | -1.52 | -1.52 | 0.00 | 5.12 | 0.00 | -- | -- | 0.00 | -23.80 | -- | -25.44 | -- | -- | -- | -- | -- | 5.91 | -- | 0.0296 | -- | -- | -- | 65.62 | -- | -- | -- |
| Shanghai Haixin Group Co Ltd | 2.39bn | 411.63m | 10.36bn | 760.00 | 34.30 | 1.47 | -- | 4.34 | 0.1376 | 0.1376 | 0.7986 | 3.22 | 0.1929 | 5.73 | 7.29 | 1,268,303.00 | 3.93 | 2.68 | 4.50 | 3.06 | 49.64 | 44.55 | 20.39 | 11.17 | 2.44 | -- | 0.0202 | 36.10 | -17.88 | 1.48 | 1.20 | 4.19 | -10.27 | 13.18 |
| JCR Pharmaceuticals Co Ltd | 4.96bn | 505.38m | 10.44bn | 934.00 | 19.98 | 1.47 | 11.07 | 2.11 | 32.68 | 32.68 | 321.38 | 443.47 | 0.4022 | 0.5095 | 3.01 | 43,049,250.00 | 4.14 | 8.66 | 6.03 | 13.46 | 74.31 | 74.51 | 10.28 | 18.24 | 1.08 | 24.78 | 0.3364 | 30.60 | 24.83 | 13.11 | 46.00 | 8.19 | 18.54 | 21.67 |
| Sichuan Huiyu Pharmaceutical Co Ltd | 2.50bn | 337.70m | 10.46bn | 1.36k | 30.99 | 1.14 | -- | 4.19 | 0.3218 | 0.3218 | 2.38 | 8.77 | 0.2222 | 1.06 | 13.03 | 739,518.20 | 2.93 | 10.41 | 3.56 | 12.76 | 83.61 | 89.89 | 13.18 | 21.42 | 2.76 | -- | 0.1296 | 20.54 | -37.92 | 76.37 | -43.86 | -- | 66.72 | -- |
| Supriya Lifescience Ltd | 1.26bn | 283.66m | 10.56bn | 448.00 | 37.22 | -- | 33.16 | 8.40 | 16.80 | 16.80 | 74.42 | -- | -- | -- | -- | 13,370,000.00 | -- | 19.08 | -- | 24.04 | 62.75 | 57.12 | 22.58 | 24.71 | -- | 92.47 | -- | 2.88 | 23.74 | 15.47 | 32.56 | 24.75 | 83.79 | -- |
| Adcock Ingram Holdings Limited | 9.64bn | 814.01m | 10.57bn | 2.39k | 12.46 | 1.60 | -- | 1.10 | 5.26 | 5.26 | 62.36 | 40.94 | 1.16 | 2.57 | 4.50 | -- | 9.80 | 10.24 | 13.97 | 14.44 | 33.38 | 30.34 | 8.44 | 9.05 | 0.9267 | -- | 0.0493 | 41.41 | 5.60 | 6.38 | -9.39 | 3.37 | -9.93 | 6.58 |
| ScinoPharm Taiwan Ltd | 1.88bn | 220.89m | 10.66bn | 1.01k | 48.39 | 1.88 | 22.24 | 5.67 | 0.5084 | 0.5084 | 4.33 | 13.12 | 0.2871 | 1.27 | 6.63 | -- | 3.37 | 2.33 | 3.69 | 2.51 | 38.89 | 41.09 | 11.76 | 9.10 | 5.00 | -- | 0.0592 | 109.25 | -2.39 | -2.00 | -18.73 | -8.31 | 16.90 | -9.35 |
| Hunan Fangsheng Pharmaceutical Co Ltd | 4.17bn | 537.54m | 10.75bn | 1.69k | 19.66 | 2.87 | -- | 2.58 | 0.5026 | 0.5026 | 3.87 | 3.44 | 0.5372 | 1.44 | 6.24 | 998,562.10 | 6.67 | 5.39 | 11.80 | 9.37 | 68.22 | 66.91 | 12.43 | 8.95 | 0.472 | 14.06 | 0.3458 | 46.47 | -9.12 | 9.15 | -34.64 | 20.68 | 23.91 | 4.75 |
| Revance Therapeutics Inc | 4.28bn | -4.98bn | 10.95bn | 597.00 | -- | -- | -- | 2.56 | -3.17 | -3.21 | 2.64 | -1.24 | 0.4466 | 1.35 | 9.18 | 408,542.70 | -51.97 | -55.55 | -61.40 | -63.20 | 71.53 | -- | -116.39 | -304.96 | 3.01 | -22.09 | 1.41 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Public Investment Corporation (SOC) Ltd.as of 30 Jun 2023 | 15.34m | 9.04% |
| Old Mutual Customised Solutions (Pty) Ltd.as of 30 Jun 2024 | 1.22m | 0.72% |
| Dimensional Fund Advisors LPas of 05 Sep 2024 | 1.17m | 0.69% |
| BlackRock Fund Advisorsas of 05 Sep 2024 | 909.79k | 0.54% |
| Abax Investments (Pty) Ltd.as of 30 Jun 2024 | 840.00k | 0.50% |
| ClucasGray Investment Management (Pty) Ltd.as of 29 Mar 2024 | 820.08k | 0.48% |
| Merchant West Investments (Pty) Ltd.as of 30 Aug 2024 | 603.38k | 0.36% |
| Centaur Asset Management Pty Ltd.as of 30 Jun 2024 | 401.79k | 0.24% |
| Ninety One SA (Pty) Ltd.as of 31 Mar 2024 | 395.45k | 0.23% |
| Camissa Asset Management Pty Ltd.as of 31 Mar 2024 | 376.04k | 0.22% |
